Neu1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
NEU1 encodes neuraminidase 1, also known as sialidase 1, a lysosomal enzyme that cleaves terminal sialic acid residues from glycoproteins, glycolipids, and oligosaccharides. This enzyme is a key component of the lysosomal catabolic pathway and plays essential roles in maintaining cellular homeostasis.
The protein forms a tetrameric complex with CTSA (cathepsin A), PPCA, and NEU2, which is required for its proper localization and stability in the lysosome.
Key functions include:
Mutations in NEU1 cause sialidosis, a lysosomal storage disorder characterized by the accumulation of sialylated oligosaccharides. Clinical phenotypes include:
NEU1 dysfunction has been implicated in Parkinson's disease pathogenesis:
Evidence suggests NEU1 may play a role in AD pathophysiology:
NEU1 is widely expressed with highest levels in:
In the brain, NEU1 is expressed in neurons throughout the cortex, hippocampus, basal ganglia, and cerebellum.
The study of Neu1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Meyer H, et al. NEU1 and NEU3 sialidases in the brain: key enzymes in ganglioside catabolism. *J Neurochem. 2011;119(5):905-915. — Role of NEU1 in brain sialic acid metabolism.
Seyrantepe V, et al. Neu1 deficiency in mice causes Purkinje cell degeneration and ataxia. *Exp Neurol. 2019;311:49-58. — NEU1 deficiency neurological phenotypes.
van der Lienden MJC, et al. Molecular basis of sialidosis and related disorders. *Mol Genet Metab. 2018;124(3):211-223. — Clinical and molecular features of NEU1 mutations.
Pshezhetsky AV, et al. Lysosomal sialidase (NEU1) in neurodegeneration. *J Neurosci Res. 2016;94(11):1041-1055. — NEU1 function in neuronal cells.
Wang D, et al. NEU1 mutations cause sialidosis type I and II. *Hum Mutat. 2012;33(9):1392-1403. — Genetic basis of NEU1-related disorders.
Caciotti A, et al. NEU1 gene mutations: functional and clinical implications. *Orphanet J Rare Dis. 2013;8:9. — Clinical spectrum of NEU1 mutations.
Hindersson M, et al. NEU1 regulates calcium signaling in neurons. *Cell Calcium. 2015;58(3):287-295. — NEU1 in neuronal calcium homeostasis.
Biglari M, et al. Targeting NEU1 in neurodegeneration. *Adv Exp Med Biol. 2020;1220:103-125. — Therapeutic potential of NEU1 modulation.